Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure

Journal of the American College of Cardiology

Volumn 32, Issue 6, 1998, Pages 1695-1700

  Hülsmann, Martin ^a   Stanek, Brigitte ^b   Frey, Bernhard ^b   Sturm, Barbara ^b   Putz, Dinah ^b   Kos, Thomas ^b   Berger, Rudolf ^b   Woloszczuk, Wolfgang ^b   Maurer, Gerald ^b   Pacher, Richard ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; NORADRENALIN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; EXERCISE TEST; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADULT; AGED; CARDIAC OUTPUT, LOW; ENDOTHELIN-1; ENDOTHELINS; EXERCISE TEST; FEMALE; HEART; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 3042835995     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00437-9     Document Type: Article

References (37)

1. Mancini DM, Eisen H, Kussmaul W, Mull RL, Edmunds H Jr., Wilson JR. Value of peak oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
2. Cohn J, Johnson G, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87 Suppl VI:VI-5-VI-16.
3. Stelken A, Younis L, Jennison S, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996;27:345-52.
4. Cohn J, Levine B, Olivari M, et al. Plasma norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311: 819-23.
5. Gottlieb S, Kukin M, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
6. Yanagisawa M, Kurihara S, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
7. Komuro I, Kurihara H, Sugiyama T, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988;238:249-52.
8. Cody R, Haas G, Binkley P, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
9. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-24.
10. McMurray JJ, Ray SG, Abdullah I, Dergie HJ, Morton JJ: Plasma endothelin in chronic heart failure. Circulation 1992;85:1374-9.
11. Pacher R, Bergler-Klein J, Globits S, et al. Plasma big endothelin-1 concentrations in congestive heart failure compared to systemic hypertension. Am J Cardiol 1993;71:1293-9.
12. Tsutamato T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin spillover in the lungs and pulmonary resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.
13. Tsutamato T, Hisanaga T, Fukai D, Wada A, Maeda Y, Kinoshita M. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76:803-8.
14. Pousset F, Issnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18: 254-8.
15. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations as compared to invasive hemdodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-41.
16. Stanek B, Frey B, Hülsmann M, et al. Validation of big endothelin plasma levels compared to established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 1997;29:595-6.
17. Krum H, Goldsmith R, Wilshire-Clement M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995;75: 1282-3.
18. Parker D, Karvelis K, Thrall J, Fröhlich J. Radionuclide ventriculography. In: Gerson M, editor. Cardiac Nuclear Medicine. New York: McGraw-Hill, 1991:81-98.
19. Wasserman K, Whipp BJ, Koyal SN, Beaver WL. Anaerobic threshold and respiratory gas exchange during exercise. J Appl Physiol 1973;35:236-43.
20. Schuller M, Stetter R, Skrabal S, Missbichler A, Woloszczuk W, Hartter E: Radioimmunoassay of immunoreactive C-terminal big-endothelin. Eur J Clin Chem Clin Biochem 1991;29:147-50.
21. Roul G, Moulichon M, Bareiss P, et al. Prognostic factors of chronic heart failure in NYHA class II or III. Value of invasive exercise haemodynamic data. Eur Heart J 1995;16:1387-98.
22. Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. Abnormal skeletal muscle bioenergetics in patients with heart failure; role of reduced muscle blood flow. Circulation 1986;73:1127-36.
23. Mancini D, Ferraro N, Tuchler M, Chance B, Wilson JB. Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus 31-nuclear magnetic resonance. Am J Cardiol 1988;62:1234-40.
24. Drexler H, Rieder U, Munzel T, Konig H, Funke E, et al. Alterations of skeletal muscle in chronic heart failure. Circulation 1992;85:1751-9.
25. Andrews R, Walsh JT, Evans A, Curtis S, Cowley AJ. Abnormalities of skeletal muscle metabolism in patients with chronic heart failure: evidence that they are present at rest. Heart 1997;77:159-63.
26. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJV. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94:2131-7.
27. Kiowski W, Suetsch G, Hunziker P, Mueller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
28. Wei C, Lerman A, Rodeheffer R, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
29. Cargill R, Kiely D, Clark R, Lipworth B. Hypoxaemia and release of endothelin-1. Thorax 1995;50:1308-10.
30. Luchner A, Borgeson DD, Stevens DL, Friedrich E, Burnett JC Jr. Pulmonary endothelin-1 gene expression is increased in experimental congestive heart failure [abstract]. Circulation 1997;1:267.
31. Teerlink JR, Löffler B, Hess P, Maire J, Lozel M, Clozel J. Role of endothelin in the maintenance of blood pressure in rats with chronic heart failure. Circulation 1994;90:2510-8.
32. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
33. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996;32:1148-54.
34. Davidson N, Coutie W, Webb D, Struthers A. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 1996;75: 576-81.
35. Krum H, Gu A, Wilshire-Clement B, et al. Changes in plasma endothelin-1 reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996;131:337-41.
36. Stanek B, Frey B, Berger R, et al. Plasma big endothelin (ET) levels during therapy predict worsening of heart failure treated with enalapril [abstract]. Eur Heart J 1997;18 Suppl:178.
37. McDonagh TA, Robb SD, Murdoch DP, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.